Oramed Pharmaceuticals, Inc. (ORMP) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1237348,
    "name": "Oramed Pharmaceuticals, Inc.",
    "stock_name": "Oramed Pharmaceuticals, Inc.",
    "full_name": "Oramed Pharmaceuticals, Inc.",
    "name_url": "stocks-analysis/oramed-pharmaceuticals-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "2.72",
    "chg": -0.03,
    "chgp": "-1.09%",
    "dir": -1,
    "prev_price": "2.75",
    "mcapval": "94.31",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US68403P2039",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "124.53 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/oramed-pharmaceuticals-inc-1237348-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Oramed Pharmaceuticals Forms Golden Cross, Signaling Bullish Breakout Ahead",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/oramed-pharmaceuticals-forms-golden-cross-signaling-bullish-breakout-ahead-3600766",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/OramedPharmaceu_goldencross_3600766.png",
        "date": "2025-10-07 19:05:56",
        "description": "Oramed Pharmaceuticals, Inc. has recently achieved a Golden Cross, indicating a potential shift in momentum. Technical indicators suggest a bullish outlook, with the stock gaining nearly 10% over the past month. However, it has faced significant challenges over the past three years, underperforming compared to the S&P 500."
      },
      {
        "title": "Is Oramed Pharmaceuticals, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-oramed-pharmaceuticals-inc-technically-bullish-or-bearish-3546730",
        "imagepath": "",
        "date": "2025-09-20 19:39:24",
        "description": "As of 11 September 2025, the technical trend for Oramed Pharmaceuticals, Inc. has changed from sideways to mildly bullish. The weekly MACD is bullish, and the monthly MACD is mildly bullish, supporting the positive outlook. Bollinger Bands are bullish on both weekly and monthly time frames. The KST and OBV indicators are also mildly bullish monthly, while the daily moving averages indicate a mildly bearish stance. \n\nIn terms of performance, the stock has returned 17.31% over the past month, significantly outperforming the S&P 500's 2.33% return, but it has underperformed over longer periods, with a 3-year return of -68.23% compared to the S&P 500's 70.41%. Overall, the current technical stance is mildly bullish, driven primarily by the positive momentum in MACD and Bollinger Bands...."
      },
      {
        "title": "Is Oramed Pharmaceuticals, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-oramed-pharmaceuticals-inc-overvalued-or-undervalued-3543241",
        "imagepath": "",
        "date": "2025-09-20 18:14:25",
        "description": "As of 15 May 2025, the valuation grade for Oramed Pharmaceuticals, Inc. has moved from does not qualify to risky. The company appears to be overvalued given its financial metrics, particularly with a Price to Book Value of 0.64 and an EV to EBITDA ratio of 2.81, which are concerning in the context of its negative returns. Additionally, the ROE stands at -20.08%, indicating significant inefficiencies in generating profit from equity.\n\nIn comparison to its peers, Esperion Therapeutics, Inc. shows a more severe valuation with an EV to EBITDA of -28.9150, while Protalix Biotherapeutics, Inc. is considered attractive with a P/E ratio of 20.0760. The stock has underperformed against the S&P 500 over the longer term, with a 3-year return of -68.23% compared to the S&P 500's 70.41%, reinforcing the notion that Oramed Pharmaceuticals is currently overvalued...."
      }
    ],
    "total": 7,
    "sid": "1237348",
    "stock_news_url": "https://www.marketsmojo.com/news/oramed-pharmaceuticals-inc-1237348"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Oramed Pharmaceuticals Forms Golden Cross, Signaling Bullish Breakout Ahead

2025-10-07 19:05:56

Oramed Pharmaceuticals, Inc. has recently achieved a Golden Cross, indicating a potential shift in momentum. Technical indicators suggest a bullish outlook, with the stock gaining nearly 10% over the past month. However, it has faced significant challenges over the past three years, underperforming compared to the S&P 500.

Is Oramed Pharmaceuticals, Inc. technically bullish or bearish?

2025-09-20 19:39:24

As of 11 September 2025, the technical trend for Oramed Pharmaceuticals, Inc. has changed from sideways to mildly bullish. The weekly MACD is bullish, and the monthly MACD is mildly bullish, supporting the positive outlook. Bollinger Bands are bullish on both weekly and monthly time frames. The KST and OBV indicators are also mildly bullish monthly, while the daily moving averages indicate a mildly bearish stance. In terms of performance, the stock has returned 17.31% over the past month, significantly outperforming the S&P 500's 2.33% return, but it has underperformed over longer periods, with a 3-year return of -68.23% compared to the S&P 500's 70.41%. Overall, the current technical stance is mildly bullish, driven primarily by the positive momentum in MACD and Bollinger Bands....

Is Oramed Pharmaceuticals, Inc. overvalued or undervalued?

2025-09-20 18:14:25

As of 15 May 2025, the valuation grade for Oramed Pharmaceuticals, Inc. has moved from does not qualify to risky. The company appears to be overvalued given its financial metrics, particularly with a Price to Book Value of 0.64 and an EV to EBITDA ratio of 2.81, which are concerning in the context of its negative returns. Additionally, the ROE stands at -20.08%, indicating significant inefficiencies in generating profit from equity. In comparison to its peers, Esperion Therapeutics, Inc. shows a more severe valuation with an EV to EBITDA of -28.9150, while Protalix Biotherapeutics, Inc. is considered attractive with a P/E ratio of 20.0760. The stock has underperformed against the S&P 500 over the longer term, with a 3-year return of -68.23% compared to the S&P 500's 70.41%, reinforcing the notion that Oramed Pharmaceuticals is currently overvalued....

View All News